Coenzyme Q10 sits in the mitochondrial membrane, shuttling electrons in the chain that produces ATP, and it is also a fat-soluble antioxidant. The body makes it, levels fall with age, and statins lower it further because they block an early step in the same synthesis pathway as cholesterol. That last fact is the basis for the most common reason people take it: muscle pain on statins.

The heart failure story is older and more serious. Failing hearts have low CoQ10, and small trials over decades suggested supplementation helped. Then a trial large enough to look at deaths was run.

In the mitochondrial electron transport chain CoQ10 carries electrons from complexes I and II to complex III, and the heart, the body's most energy-hungry muscle, depends on that chain running well. The proposal in heart failure is that restoring a depleted cofactor improves energy production in a struggling muscle. In statin myopathy the proposal is that statins deplete muscle CoQ10 and that replacing it relieves the symptoms, though whether depletion actually causes the symptoms has never been settled. As an antioxidant it protects membrane lipids from oxidation.

Heart failure: one positive trial, uncertain pooled verdict. Q-SYMBIO randomized 420 patients with moderate to severe heart failure to CoQ10 or placebo for two years on top of standard therapy. Short-term symptom and biomarker endpoints at 16 weeks did not change. The two-year composite of major cardiovascular events was reached by 15% on CoQ10 and 26% on placebo, with cardiovascular and all-cause mortality both lower. The 2021 Cochrane review of eleven trials in 1,573 people was more cautious, noting small samples and differences in dose, follow-up and outcomes across trials, and rated the evidence as insufficient to recommend it.

Statin muscle symptoms. A 2018 meta-analysis of twelve randomized trials in 575 patients found CoQ10 reduced muscle pain, weakness, cramps and tiredness on statins, with no change in creatine kinase, the blood marker of muscle damage. Symptoms improved; the objective marker did not.

Statin metabolic effects. The LIFESTAT trial gave 35 people on high-dose simvastatin eight weeks of CoQ10 or placebo and measured insulin sensitivity by the gold-standard clamp method: no change in whole-body insulin sensitivity, glucose handling or insulin secretion, with a possible improvement in hepatic insulin sensitivity.

Fatigue, aging, fertility, migraine. Small trials, mixed results, nothing of the size of Q-SYMBIO.

CoQ10 is well tolerated across trials of up to two years; mild stomach upset and insomnia are the usual complaints. It can reduce the effect of warfarin, because it is structurally related to vitamin K, so people on that anticoagulant should not add it without their clinician knowing. It can also lower blood pressure slightly, which matters for people on antihypertensives. Long-term data beyond a few years do not exist.

CoQ10 is a dietary supplement in the United States, the United Kingdom and the European Union, with no review of its claims. In Japan it is approved as a medicine for heart failure, a status it has held since the 1970s. That approval predates the modern trials and is not shared by any Western regulator. Ubiquinol, the reduced form, is marketed as better absorbed; the comparative evidence is thin.